JP Morgan Chase’s SpringWorks Therapeutics SWTX Stock Holding History

JP Morgan Chase’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-37,500	Closed	-$1.76M	–	7713
2025 Q2	$1.76M	Buy	+37,500	New	+$1.67M	﹤0.01%	4006
2022 Q4	–	Sell	-123,200	Closed	-$3.52M	–	6983
2022 Q3	$3.52M	Buy	+123,200	New	+$3.53M	﹤0.01%	3025

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

JP Morgan Chase's SWTX Position: Q3 2025 in Review

JP Morgan Chase sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 1,148,914 shares — an estimated $54M sold.

JP Morgan Chase first reported a position in SWTX in Q4 2019 and held it in 23 quarters. The position peaked at $54M in Q2 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

JP Morgan Chase reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
JP Morgan Chase sold 1,148,914 SpringWorks Therapeutics shares in Q3 2025, an estimated $54M.
JP Morgan Chase first reported a position in SpringWorks Therapeutics in Q4 2019 and held it in 23 quarters.
JP Morgan Chase's SpringWorks Therapeutics position peaked at $54M in Q2 2025.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on JP Morgan Chase's 13F filing for Q3 2025, filed 7 Nov 2025.